2010 Guidelines of the Taiwan society of cardiology for the management of hypertension

Journal of the Formosan Medical Association

Volumn 109, Issue 10, 2010, Pages 740-773

  Chiang, Chern En ^a   Wang, Tzung Dau ^b   Li, Yi Heng ^c   Lin, Tsung Hsien ^d   Chien, Kuo Liong ^e   Yeh, Hung I ^b   Shyu, Kou Gi ^f   Tsai, Wei Chuen ^c   Chao, Ting Hsing ^g   Hwang, Juey Jen ^b   Chiang, Fu Tien ^h   Chen, Jyh Hong ^c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Blood pressure; Disease management; Drug therapy; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPROSARTAN; ERYTHROPOIETIN; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; LOOP DIURETIC AGENT; LOSARTAN; NICARDIPINE; NITRENDIPINE; NITROPRUSSIDE SODIUM; PERINDOPRIL; PHENTOLAMINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ACROMEGALY; ADD ON THERAPY; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; AORTA COARCTATION; AORTA PRESSURE; ARTERY DISEASE; ARTICLE; ASIAN; ASTHMA; ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; BEDTIME DOSAGE; BLOOD PRESSURE MONITORING; BRONCHOSPASM; CARCINOID SYNDROME; CARDIOLOGY; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CUSHING SYNDROME; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSAUTONOMIA; ESSENTIAL HYPERTENSION; EXERCISE; FLUSHING; GERIATRIC DISORDER; GUILLAIN BARRE SYNDROME; HEALTH CARE COST; HEART BLOCK; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE SUBSTITUTION; HUMAN; HYPERKALEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERTHYROIDISM; HYPOKALEMIA; HYPOTHYROIDISM; INCIDENCE; INTRACRANIAL HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; LIDDLE SYNDROME; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; METABOLIC DISORDER; METHEMOGLOBINEMIA; MICROALBUMINURIA; MONOTHERAPY; MORNING DOSAGE; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PHLEBITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; QUADRIPLEGIA; RENOVASCULAR DISEASE; SECONDARY PREVENTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SMOKING CESSATION; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CARDIOLOGY; HUMANS; HYPERTENSION; SOCIETIES, MEDICAL; TAIWAN;

EID: 77958128138     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60120-9     Document Type: Article

References (208)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
5. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007, 115:2761-2788.
6. Lawes CM, Vander HS, Rodgers A Global burden of blood-pressure-related disease, 2001. Lancet 2008, 371:1513-1518.
7. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 2002, 287:1003-1010.
8. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
9. Chiang CE, Chen CH Hypertension in the Asia-Pacific region. J Hum Hypertens 2008, 22:441-443.
10. Su TC, Bai CH, Chang HY, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens 2008, 26:600-606.
11. Chien KL, Hsu HC, Sung FC, et al. Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan. J Hypertens 2007, 25:1355-1361.
12. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991-997.
13. Martiniuk AL, Lee CM, Lawes CM, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007, 25:73-79.
14. Rodgers A, Chapman N, Woodward M, et al. Perindopril-based blood pressure lowering in individuals with cere-brovascular disease: consistency of benefits by age, sex and region. J Hypertens 2004, 22:653-659.
15. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75.
16. Pan WH, Chang HY, Yeh WT, et al. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. J Hum Hypertens 2001, 15:793-798.
17. Choi KM, Park HS, Han JH, et al. Prevalence of prehyper-tension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006, 24:1515-1521.
18. Asai Y, Ishikawa S, Kayaba K, et al. Prevalence, awareness, treatment, and control of hypertension in Japanese rural communities. Nippon Koshu Eisei Zasshi 2001, 48:827-836.
19. Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008, 118:2679-2686.
20. Bureau of Health Promotion Department of Health [Date accessed: September 27, 2010]. http://www.bhp.doh.tw/health91/pdf/3H/06.pdf.
21. Carretero OA, Oparil S Essential hypertension: part I: definition and etiology. Circulation 2000, 101:329-335.
22. th century. 1. Hypertension and genes. Intern Med 2001, 40:144-147.
23. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
24. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
25. Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol 2008, 124:6-21.
26. Pickering TG, Shimbo D, Haas D Ambulatory blood-pressure monitoring. N Engl J Med 2006, 354:2368-2374.
27. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008, 52:1-9.
28. Pickering TG, White WB ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2008, 10:850-855.
29. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008, 26:1505-1526.
30. Stergiou GS, Karpettas N, Protogerou A, et al. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens 2009, 23:654-658.
31. Parati G, Omboni S, Bilo G Why is out-of-office blood pressure measurement needed? Home blood pressure measurements will increasingly replace ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Hypertension 2009, 54:181-187.
32. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
33. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001, 103:1245-1249.
34. Alli C, Avanzini F, Bettelli G, et al. The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med 1999, 159:1205-1212.
35. Okayama A, Kadowaki T, Okamura T, et al. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80*). J Hypertens 2006, 24:459-462.
36. Williams B, Lindholm LH, Sever P Systolic pressure is all that matters. Lancet 2008, 371:2219-2221.
37. Wang JG, Staessen JA, Franklin SS, et al. Systolic and dias-tolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005, 45:907-913.
38. Mancia G, Grassi G Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461-1464.
39. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003, 348:2407-2415.
40. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study. Hypertension 2005, 46:156-161.
41. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Circulation 2005, 111:1777-1783.
42. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008, 51:55-61.
43. Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007, 115:2145-2152.
44. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998, 16:971-975.
45. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004, 291:1342-1349.
46. Fagard RH, Van Den BC, De Cort P Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005, 19:801-807.
47. dabl Education Trust [Date accessed: September 2 7, 2010]. http://dableducational.org.
48. British Hypertension Society [Date accessed: September 2 7, 2010]. http://www.bhsoc.org/default.stm.
49. Stergiou GS, Parati G The optimal schedule for self-monitoring of blood pressure by patients at home. J Hypertens 2007, 25:1992-1997.
50. Eguchi K, Kuruvilla S, Ogedegbe G, et al. What is the optimal interval between successive home blood pressure readings using an automated oscillometric device?. J Hypertens 2009, 27:1172-1177.
51. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008, 299:2857-2867.
52. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring: 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005, 46:508-515.
53. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006, 47:846-853.
54. Ben Dov IZ, Kark JD, Mekler J, et al. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. J Hypertens 2008, 26:699-705.
55. Agarwal R, Andersen MJ Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006, 69:406-411.
56. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study). Circulation 2001, 104:1385-1392.
57. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007, 50:197-203.
58. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?. J Hypertens 2009, 27:461-467.
59. Vlachopoulos C, Aznaouridis K, Stefanadis C Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
60. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
61. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-266.
62. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
63. Hallan S, Asberg A, Lindberg M, et al. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004, 44:84-93.
64. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008, 371:2173-2182.
65. Task FM, Ryden L, Standl E, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
66. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
67. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
68. Cuspidi C, Ambrosioni E, Mancia G, et al. Role of echocar-diography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002, 20:1307-1314.
69. Hall WD Resistant hypertension, secondary hypertension, and hypertensive crises. Cardiol Clin 2002, 20:281-289.
70. Safian RD, Textor SC Renal-artery stenosis. N Engl J Med 2001, 344:431-442.
71. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921-1926.
72. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
73. Wu VC, Chueh SC, Chang HW, et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM 2008, 101:13-22.
74. King DE, Mainous AG, Carnemolla M, et al. Adherence to healthy lifestyle habits in US adults, 1988-2006. Am J Med 2009, 122:528-534.
75. Chobanian AV The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009, 361:878-887.
76. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006, 24:215-233.
77. Chien KL, Hsu HC, Chen PC, et al. Urinary sodium and potassium excretion and risk of hypertension in Chinese: report from a community-based cohort study in Taiwan. J Hypertens 2008, 26:1750-1756.
78. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885.
79. Strazzullo P, D'Elia L, Kandala NB, et al. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ 2009, 339:b4567.
80. Palar K, Sturm R Potential societal savings from reduced sodium consumption in the U.S. adult population. Am J Health Promot 2009, 24:49-57.
81. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010, 590-599.
82. Chen J, Gu D, Huang J, et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet 2009, 373:829-835.
83. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.
84. Alderman MH Non-pharmacological treatment of hypertension. Lancet 1994, 344:307-311.
85. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001, 38:1112-1117.
86. Grotto I, Grossman E, Huerta M, et al. Prevalence of pre-hypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 2006, 48:254-259.
87. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
88. Carretero OA, Oparil S Essential hypertension: part II: treatment. Circulation 2000, 101:446-453.
89. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006, 47:296-308.
90. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336:1117-1124.
91. Moore TJ, Conlin PR, Ard J, et al. DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension. Hypertension 2001, 38:155-158.
92. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3-10.
93. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:11-13.
94. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
95. Cornelissen VA, Fagard RH Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005, 46:667-675.
96. Kaplan NM, Opie LH Controversies in hypertension. Lancet 2006, 367:168-176.
97. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
98. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007, 167:2431-2436.
99. Law MR, Morris JK, Wald NJ Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
100. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
101. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
102. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.
103. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
104. Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005, 46:1053-1059.
105. Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of val-sartan. J Hypertens 2005, 23:1913-1922.
106. Hermida RC, Ayala DE, Fernandez JR, et al. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007, 50:715-722.
107. Hermida RC, Ayala DE Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009, 54:40-46.
108. Hermida RC, Calvo C, Ayala DE, et al. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005, 46:960-968.
109. Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007, 50:908-917.
110. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
111. Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, mul-ticentre trial (the EUROPA study). Lancet 2003, 362:782-788.
112. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihyperten-sive agents on cardiovascular events in patients with coronary disease and normal blood Pressure: the CAMELOT Study: a randomized controlled trial. JAMA 2004, 292:2217-2225.
113. Patel A, Macmahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovas-cular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
114. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;online first: NEJMoa1001286.
115. Waeber B, Burnier M, Brunner HR Compliance with anti-hypertensive therapy. Clin Exp Hypertens 1999, 21:973-985.
116. Williams B Hypertension and the "J-Curve" J Am Coll Cardiol 2009, 54:1835-1836.
117. Messerli FH, Panjrath GS The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?. J Am Coll Cardiol 2009, 54:1827-1834.
118. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006, 144:884-893.
119. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
120. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898.
121. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
122. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihy-pertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
123. Elliott WJ, Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
124. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normogly-cemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401-1409.
125. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
126. Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007, 25:1311-1317.
127. Moser M, Setaro JF Resistant or difficult-to-control hypertension. N Engl J Med 2006, 355:385-392.
128. American Diabetes Association Standards of medical care in diabetes-2009. Diabetes Care 2009, 32:S13-S61.
129. Conlin PR, Gerth WC, Fox J, et al. Four-Year persistence patterns among patients initiating therapy with the angio-tensin II receptor antagonist losartan versus other artihy-pertensive drug classes. Clin Ther 2001, 23:1999-2010.
130. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative anti-hypertensive effects of hydrochlorothiazide and chlor-thalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
131. Lindholm LH, Carlberg B, Samuelsson O Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
132. Wiysonge C, Bradley H, Mayosi B, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, CD002003.
133. Bangalore S, Sawhney S, Messerli FH Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008, 52:1482-1489.
134. Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009, 54:1154-1161.
135. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
136. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
137. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
138. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
139. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
140. The ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
141. Musini VM, Fortin PM, Bassett K, et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008, CD007066.
142. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
143. Lee HY, Oh BH Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther 2009, 7:251-257.
144. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihy-pertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283:1967-1975.
145. Chapman N, Chang CL, Dahlof B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihy-pertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008, 118:42-48.
146. Pitt B, Zannad F, Remme WJ, et al. The effect of spirono-lactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
147. Chapman N, Dobson J, Wilson S, et al. Effect of spirono-lactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
148. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
149. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007, 21:220-224.
150. Messerli FH, Oparil S, Feng Z Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus highdose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000, 86:1182-1187.
151. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004, 328:634-640.
152. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
153. Messerli FH The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009, 53:468-470.
154. Elliott WJ Improving outcomes in hypertensive patients: focus on adherence and persistence with antihyperten-sive therapy. J Clin Hypertens (Greenwich) 2009, 11:376-382.
155. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713-719.
156. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006, 8:850-857.
157. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009, 53:646-653.
158. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
159. Parra D, Rosenstein R Benazepril plus amlodipine or hy-drochlorothiazide for hypertension. N Engl J Med 2009, 360:1147-1148.
160. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior my-ocardial infarction. N Engl J Med 1998, 339:229-234.
161. Executive Summary: standards of medical care in diabetes (2010). Diabetes Care 2010, 33:S4-S10.
162. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisol-dipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
163. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.
164. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
165. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
166. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
167. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007, 115:e478-e534.
168. Turnbull F Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
169. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
170. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with ni-trendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.
171. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237.
172. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002, 162:1636-1643.
173. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
174. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
175. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003, 21:707-716.
176. Murakami Y, Hozawa A, Okamura T, et al. Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension 2008, 51:1483-1491.
177. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994, 121:355-362.
178. Port S, Demer L, Jennrich R, et al. Systolic blood pressure and mortality. Lancet 2000, 355:175-180.
179. Bemmel Tv, Gussekloo J, Westendorp RG, et al. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. J Hypertens 2006, 24:287-292.
180. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihy-pertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997, 126:761-767.
181. Farquhar CM, Marjoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, CD004143.
182. Duley L, Meher S, Abalos E Management of pre-eclampsia. BMJ 2006, 332:463-468.
183. Elliott WJ Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis 2006, 48:316-325.
184. Marik PE, Varon J Hypertensive crises: challenges and management. Chest 2007, 131:1949-1962.
185. Davis BA, Crook JE, Vestal RE, et al. Prevalence of reno-vascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979, 301:1273-1276.
186. Sarafidis PA, Bakris GL Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749-1757.
187. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005, 18:619-626.
188. Park J, Campese V Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich) 2007, 9:7-12.
189. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
190. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-678.
191. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
192. Pedersen TR Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med 1985, 313:1055-1058.
193. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007, 369:1431-1439.
194. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-90.
195. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685-691.
196. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of cap-topril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
197. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
198. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocar-dial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
199. Cohn JN, Tognoni G A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
200. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
201. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
202. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
203. Tasaki H Electrophysiological study of the striated muscle cells of the extrapulmonary vein of the guinea-pig. Jpn Circ J 1969, 33:1087-1098.
204. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005, 46:386-392.
205. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005, 23:2157-2172.
206. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
207. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265:3255-3264.
208. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998, 16:1823-1829.